Online inquiry

IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14499MR)

This product GTTS-WQ14499MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CNR1 gene. The antibody can be applied in Non-alcoholic fatty liver disease (NAFLD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001160226.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1268
UniProt ID P21554
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14499MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6230MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ6544MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ12365MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ10878MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ12542MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ11946MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ2652MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ15850MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-18087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW